picture: Immatics

Harpreet Singh becomes CEO of Immatics

Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical Company active in the discovery and development of T-cell redirecting cancer immunotherapies, today announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer (CEO).

Harpreet Singh has most recently been President and CEO of Immatics US and Chief Scientific Officer (CSO) of the Company, having co-founded Immatics. He has been instrumental in growing the Company from a start-up to a leading player in the field of immuno-oncology.

Peter Chambré, Chairman of Immatics, says: “The Board is delighted to appoint Harpreet as CEO to lead Immatics in the next phase of its development, as the Company progresses its pipeline of immunotherapy candidates. Harpreet is an exceptional organizational leader and scientist and over the past three years has led the building of the Immatics US organization and creation of Immatics’ clinical pipeline and capabilities in adoptive cellular therapy, as well as guiding the Company’s overall scientific development since its early days. We are very excited about the prospects and opportunities for Immatics, with Harpreet as CEO.”